Sector Irradiation vs. Whole Brain Irradiation After Resection of Singular Brain Metastasis-A Prospective Randomized Monocentric Trial

Johannes Kerschbaumer, Daniel Pinggera, Bernhard Holzner, Margarete Delazer, Thomas Bodner, Elfriede Karner, Lucie Dostal, Irma Kvitsaridze, Danijela Minasch, Claudius Thomé, Marcel Seiz-Rosenhagen, Meinhard Nevinny-Stickel, Christian F Freyschlag, Johannes Kerschbaumer, Daniel Pinggera, Bernhard Holzner, Margarete Delazer, Thomas Bodner, Elfriede Karner, Lucie Dostal, Irma Kvitsaridze, Danijela Minasch, Claudius Thomé, Marcel Seiz-Rosenhagen, Meinhard Nevinny-Stickel, Christian F Freyschlag

Abstract

To minimize recurrence following resection of a cerebral metastasis, whole-brain irradiation therapy (WBRT) has been established as the adjuvant standard of care. With prolonged overall survival in cancer patients, deleterious effects of WBRT gain relevance. Sector irradiation (SR) aims to spare uninvolved brain tissue by applying the irradiation to the resection cavity and the tumor bed. 40 were randomized to receive either WBRT (n = 18) or SR (n = 22) following resection of a singular brain metastasis. Local tumor control was satisfactory in both groups. Recurrence was observed earlier in the SR (median 3 months, 1-6) than in the WBRT cohort (median 8 months, 7-9) (HR, 0.63; 95% CI, 0.03-10.62). Seventeen patients experienced a distant intracranial recurrence. Most relapses (n = 15) occurred in the SR cohort, whereas only two patients in the WBRT group had new distant tumor manifestation (HR, 6.59; 95% CI, 1.71-11.49; p = 0.002). Median overall survival (OS) was 15.5 months (range: 1-61) with longer OS in the SR group (16 months, 1-61) than in the WBRT group (13 months, 3-52), without statistical significance (HR, 0.55; 95% CI, 0.69-3.64). Concerning neurocognition, patients in the SR group improved in the follow-up assessments, while this was not observed in the WBRT group. There were positive signals in terms of QOL within the SR group, but no significant differences in the global QLQ and QLQ-C30 summary scores were found. Our results indicate comparable efficacy of SR in terms of local control, with better maintenance of neurocognitive function. Unsurprisingly, more distant intracranial relapses occurred. Clinical Trial Registration: ClinicalTrials.gov, identifier NCT01667640.

Keywords: brain metastases; neuropsychology; quality of life; radiotherapy; stereotactic radiosurgery (SRS).

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Kerschbaumer, Pinggera, Holzner, Delazer, Bodner, Karner, Dostal, Kvitsaridze, Minasch, Thomé, Seiz-Rosenhagen, Nevinny-Stickel and Freyschlag.

Figures

Figure 1
Figure 1
Treatment algorithm.
Figure 2
Figure 2
Kaplan-Meier estimates of overall survival, freedom form local and distant recurrence and systemic progression.
Figure 3
Figure 3
Quality of life assessment.

References

    1. Chamberlain MC. Brain metastases: a medical neuro-oncology perspective. Expert Rev Neurother (2010) 10:563–73. 10.1586/ern.10.30
    1. Baumert BG, Rutten I, Dehing-Oberije C, Twijnstra A, Dirx MJ, Debougnoux-Huppertz RM, et al. A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiat Oncology Biology Phys (2006) 66:187–94. 10.1016/j.ijrobp.2006.03.050
    1. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol (2011) 29:134–41. 10.1200/JCO.2010.30.1655
    1. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. New Engl J Med (1990) 322:494–500. 10.1056/NEJM199002223220802
    1. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA J Am Med Assoc (1998) 280:1485–9. 10.1001/jama.280.17.1485
    1. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology (1989) 39:789–96. 10.1212/WNL.39.6.789
    1. Nieder C, Schwerdtfeger K, Steudel WI, Schnabel K. Patterns of relapse and late toxicity after resection and whole-brain radiotherapy for solitary brain metastases. Strahlenther Onkol (1998) 174:275–8. 10.1007/BF03038721
    1. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA J Am Med Assoc (2006) 295:2483–91. 10.1001/jama.295.21.2483
    1. Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol (2017) 18:1049–60. 10.1016/S1470-2045(17)30441-2
    1. Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol (2017) 18(8):1040–8. 10.1016/S1470-2045(17)30414-X
    1. Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA J Am Med Assoc (2016) 316:401–9. 10.1001/jama.2016.9839
    1. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol (2009) 10:1037–44. 10.1016/S1470-2045(09)70263-3
    1. Albert FK, Forsting M, Sartor K, Adams HP, Kunze S. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery (1994) 34:45–60; discussion 60-1. 10.1227/00006123-199401000-00008
    1. Forsting M, Albert FK, Kunze S, Adams HP, Zenner D, Sartor K. Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns. AJNR. Am J Neuroradiology (1993) 14:77–87.
    1. Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, et al. Response Assessment in Neuro-Oncology, Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol (2015) 16:e270–8. 10.1016/S1470-2045(15)70057-4
    1. Helmstaedter C, Durwen HF. VLMT: Verbaler Lern- und Merkfähigkeitstest: Ein praktikables und differenziertes Instrumentarium zur Prüfung der verbalen Gedächtnisleistungen [VLMT: A useful tool to assess and differentiate verbal memory performance]. Schweizer Archiv für Neurologie Neurochirurgie und Psychiatr (1990) 141(1):21–30.
    1. Lutz MT, Helmstaedter C. EpiTrack: tracking cognitive side effects of medication on attention and executive functions in patients with epilepsy. Epilepsy Behav (2005) 7:708–14. 10.1016/j.yebeh.2005.08.015
    1. Bäumler G, Stroop JR. Farbe-Wort-Interferenztest nach JR Stroop (FWIT). Hogrefe, Verlag für Psychologie. (1985).
    1. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 12:189–98. 10.1016/0022-3956(75)90026-6
    1. Erharter A, Giesinger J, Kemmler G, Schauer-Maurer G, Stockhammer G, Muigg A, et al. Implementation of computer-based quality-of-life monitoring in brain tumor outpatients in routine clinical practice. J Pain Symptom Manage (2010) 39:219–29. 10.1016/j.jpainsymman.2009.06.015
    1. Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY. Leptomeningeal metastases from solid malignancy: a review. J Neuro-oncology (2005) 75:85–99. 10.1007/s11060-004-8101-x
    1. Jung JM, Kim S, Joo J, Shin KH, Gwak HS, Lee SH. Incidence and risk factors for leptomeningeal carcinomatosis in breast cancer patients with parenchymal brain metastases. J Korean Neurosurgical Soc (2012) 52:193–9. 10.3340/jkns.2012.52.3.193
    1. Siomin VE, Vogelbaum MA, Kanner AA, Lee SY, Suh JH, Barnett GH. Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery. J Neuro-oncology (2004) 67:115–21. 10.1023/B:NEON.0000021785.00660.2b
    1. Ojerholm E, Lee JY, Thawani JP, Miller D, O’Rourke DM, Dorsey JF, et al. Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis. J Neurosurgery (2014) 121(Suppl):75–83. 10.3171/2014.6.GKS14708
    1. Hashimoto K, Narita Y, Miyakita Y, Ohno M, Sumi M, Mayahara H, et al. Comparison of clinical outcomes of surgery followed by local brain radiotherapy and surgery followed by whole brain radiotherapy in patients with single brain metastasis: single-center retrospective analysis. Int J Radiat Oncology Biology Phys (2011) 81:e475–80. 10.1016/j.ijrobp.2011.02.016
    1. Iwai Y, Yamanaka K, Yasui T. Boost radiosurgery for treatment of brain metastases after surgical resections. Surg Neurol (2008) 69:181–6; discussion 186. 10.1016/j.surneu.2007.07.008
    1. Jensen CA, Chan MD, McCoy TP, Bourland JD, deGuzman AF, Ellis TL, et al. Cavity-directed radiosurgery as adjuvant therapy after resection of a brain metastasis. J Neurosurgery (2011) 114:1585–91. 10.3171/2010.11.JNS10939
    1. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol (2013) 15:1429–37. 10.1093/neuonc/not114

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅